IL-35 and RANKL Synergistically Induce Osteoclastogenesis in RAW264 Mouse Monocytic Cells. 2020

Yosuke Kamiya, and Takeshi Kikuchi, and Hisashi Goto, and Iichiro Okabe, and Yuhei Takayanagi, and Yuki Suzuki, and Noritaka Sawada, and Teppei Okabe, and Yuki Suzuki, and Shun Kondo, and Jun-Ichiro Hayashi, and Akio Mitani
Department of Periodontology, School of Dentistry, Aichi Gakuin University, 2-11 Suemori-dori, Chikusa-ku, Nagoya 464-8651, Japan.

Interleukin (IL)-35 is an immunosuppressive cytokine mainly produced by regulatory T cells. IL-35 mediates immunological functions by suppressing the inflammatory immune response. However, the role of IL-35 in bone-destructive diseases remains unclear, especially in terms of osteoclastogenesis. Therefore, the current study investigated the synergistic effect of IL-35 on osteoclastogenesis that is involved the pathogeneses of periodontitis and rheumatoid arthritis. Osteoclastic differentiation and osteoclastogenesis of RAW264 (RAW) cells induced by receptor activator of nuclear factor (NF)-κB ligand (RANKL) and IL-35 were evaluated by tartrate-resistant acid phosphate staining, hydroxyapatite resorption assays, and quantitative polymerase chain reaction. The effect of IL-35 on RANKL-stimulated signaling pathways was assessed by Western blot analysis. Costimulation of RAW cells by RANKL and IL-35 induced osteoclastogenesis significantly compared with stimulation by RANKL alone. Phosphorylations of extracellular signal-regulated kinase (ERK) and p38 mitogen-activated protein kinase tended to be increased by RANKL and IL-35 compared with RANKL or IL-35 alone. Additionally, the osteoclastogenesis induced by RANKL and IL-35 was suppressed by inhibition of ERK. In this study, IL-35 and RANKL induced osteoclastogenesis synergistically. Previous reports have shown that IL-35 suppresses the differentiation of osteoclasts. Therefore, IL-35 might play dual roles of destruction and protection in osteoclastogenesis.

UI MeSH Term Description Entries
D007378 Interleukins Soluble factors which stimulate growth-related activities of leukocytes as well as other cell types. They enhance cell proliferation and differentiation, DNA synthesis, secretion of other biologically active molecules and responses to immune and inflammatory stimuli. Interleukin
D009000 Monocytes Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles. Monocyte
D010010 Osteoclasts A large multinuclear cell associated with the BONE RESORPTION. An odontoclast, also called cementoclast, is cytomorphologically the same as an osteoclast and is involved in CEMENTUM resorption. Odontoclasts,Cementoclast,Cementoclasts,Odontoclast,Osteoclast
D002454 Cell Differentiation Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs. Differentiation, Cell,Cell Differentiations,Differentiations, Cell
D000067996 RAW 264.7 Cells A transformed macrophage cell line isolated from ASCITES of mice infected with ABELSON MURINE LEUKEMIA VIRUS. RAW 264.7 Cell Line,264.7 Cell, RAW,264.7 Cells, RAW,Cell, RAW 264.7,Cells, RAW 264.7,RAW 264.7 Cell
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D053245 RANK Ligand A transmembrane protein belonging to the tumor necrosis factor superfamily that specifically binds RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B and OSTEOPROTEGERIN. It plays an important role in regulating OSTEOCLAST differentiation and activation. Tumor Necrosis Factor Ligand Superfamily Member 11,CD254 Antigen,OPGL Protein,Osteoclast Differentiation Factor,Osteoprotegerin Ligand,RANKL Protein,Receptor Activator of Nuclear Factor-kappa B Ligand,Receptor Activator of Nuclear Factor-kappaB Ligand,TNF Superfamily, Member 11,TRANCE Protein,Tumor Necrosis Factor-Related Activation-Induced Cytokine,Antigen, CD254,Differentiation Factor, Osteoclast,Receptor Activator of Nuclear Factor kappa B Ligand,Receptor Activator of Nuclear Factor kappaB Ligand,Tumor Necrosis Factor Related Activation Induced Cytokine
D020935 MAP Kinase Signaling System An intracellular signaling system involving the mitogen-activated protein kinase cascades (three-membered protein kinase cascades). Various upstream activators, which act in response to extracellular stimuli, trigger the cascades by activating the first member of a cascade, MAP KINASE KINASE KINASES; (MAPKKKs). Activated MAPKKKs phosphorylate MITOGEN-ACTIVATED PROTEIN KINASE KINASES which in turn phosphorylate the MITOGEN-ACTIVATED PROTEIN KINASES; (MAPKs). The MAPKs then act on various downstream targets to affect gene expression. In mammals, there are several distinct MAP kinase pathways including the ERK (extracellular signal-regulated kinase) pathway, the SAPK/JNK (stress-activated protein kinase/c-jun kinase) pathway, and the p38 kinase pathway. There is some sharing of components among the pathways depending on which stimulus originates activation of the cascade. MAP Kinase Cascade,MAP Kinase Module,MAP Kinase Signaling Cascade,MAP Kinase Signaling Pathway,MAP Kinase Signaling Pathways,ERK Pathway,ERK Signal Tranduction Pathway,ERK1 and ERK2 Pathway,ERK1-2 Pathway,JNK Pathway,JNK Signaling Pathway,MAP Kinase Modules,MAP Kinase Signaling Cascades,MEK-ERK Pathway,p38 Kinase Pathway,p38 Kinase Signaling Pathway,Cascade, MAP Kinase,ERK Pathways,ERK1 2 Pathway,ERK1-2 Pathways,JNK Pathways,JNK Signaling Pathways,Kinase Cascade, MAP,Kinase Pathway, p38,Kinase Pathways, p38,MAP Kinase Cascades,MEK ERK Pathway,MEK-ERK Pathways,Module, MAP Kinase,Pathway, ERK,Pathway, ERK1-2,Pathway, JNK,Pathway, JNK Signaling,Pathway, MEK-ERK,Pathway, p38 Kinase,Pathways, ERK,Pathways, ERK1-2,Pathways, JNK,Pathways, JNK Signaling,Pathways, MEK-ERK,Pathways, p38 Kinase,Signaling Pathway, JNK,Signaling Pathways, JNK,p38 Kinase Pathways

Related Publications

Yosuke Kamiya, and Takeshi Kikuchi, and Hisashi Goto, and Iichiro Okabe, and Yuhei Takayanagi, and Yuki Suzuki, and Noritaka Sawada, and Teppei Okabe, and Yuki Suzuki, and Shun Kondo, and Jun-Ichiro Hayashi, and Akio Mitani
September 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research,
Yosuke Kamiya, and Takeshi Kikuchi, and Hisashi Goto, and Iichiro Okabe, and Yuhei Takayanagi, and Yuki Suzuki, and Noritaka Sawada, and Teppei Okabe, and Yuki Suzuki, and Shun Kondo, and Jun-Ichiro Hayashi, and Akio Mitani
December 2022, International journal of molecular sciences,
Yosuke Kamiya, and Takeshi Kikuchi, and Hisashi Goto, and Iichiro Okabe, and Yuhei Takayanagi, and Yuki Suzuki, and Noritaka Sawada, and Teppei Okabe, and Yuki Suzuki, and Shun Kondo, and Jun-Ichiro Hayashi, and Akio Mitani
November 2022, Inflammation research : official journal of the European Histamine Research Society ... [et al.],
Yosuke Kamiya, and Takeshi Kikuchi, and Hisashi Goto, and Iichiro Okabe, and Yuhei Takayanagi, and Yuki Suzuki, and Noritaka Sawada, and Teppei Okabe, and Yuki Suzuki, and Shun Kondo, and Jun-Ichiro Hayashi, and Akio Mitani
December 2012, Journal of autoimmunity,
Yosuke Kamiya, and Takeshi Kikuchi, and Hisashi Goto, and Iichiro Okabe, and Yuhei Takayanagi, and Yuki Suzuki, and Noritaka Sawada, and Teppei Okabe, and Yuki Suzuki, and Shun Kondo, and Jun-Ichiro Hayashi, and Akio Mitani
April 2015, Molecular and cellular biochemistry,
Yosuke Kamiya, and Takeshi Kikuchi, and Hisashi Goto, and Iichiro Okabe, and Yuhei Takayanagi, and Yuki Suzuki, and Noritaka Sawada, and Teppei Okabe, and Yuki Suzuki, and Shun Kondo, and Jun-Ichiro Hayashi, and Akio Mitani
January 2015, Biological & pharmaceutical bulletin,
Yosuke Kamiya, and Takeshi Kikuchi, and Hisashi Goto, and Iichiro Okabe, and Yuhei Takayanagi, and Yuki Suzuki, and Noritaka Sawada, and Teppei Okabe, and Yuki Suzuki, and Shun Kondo, and Jun-Ichiro Hayashi, and Akio Mitani
January 2020, Biological & pharmaceutical bulletin,
Yosuke Kamiya, and Takeshi Kikuchi, and Hisashi Goto, and Iichiro Okabe, and Yuhei Takayanagi, and Yuki Suzuki, and Noritaka Sawada, and Teppei Okabe, and Yuki Suzuki, and Shun Kondo, and Jun-Ichiro Hayashi, and Akio Mitani
January 2011, Journal of pharmacological sciences,
Yosuke Kamiya, and Takeshi Kikuchi, and Hisashi Goto, and Iichiro Okabe, and Yuhei Takayanagi, and Yuki Suzuki, and Noritaka Sawada, and Teppei Okabe, and Yuki Suzuki, and Shun Kondo, and Jun-Ichiro Hayashi, and Akio Mitani
October 2011, The Journal of pathology,
Yosuke Kamiya, and Takeshi Kikuchi, and Hisashi Goto, and Iichiro Okabe, and Yuhei Takayanagi, and Yuki Suzuki, and Noritaka Sawada, and Teppei Okabe, and Yuki Suzuki, and Shun Kondo, and Jun-Ichiro Hayashi, and Akio Mitani
September 2013, Journal of immunology (Baltimore, Md. : 1950),
Copied contents to your clipboard!